Patent ID: 9074001
Filing Date: 2015-07-07
Classification: A61K,A61P,C07K

Abstract:
1. A vaccine comprising an M. tuberculosis antigen polypeptide, which is constitutively expressed during infection with M. tuberculosis or a nucleic acid encoding said M. tuberculosis antigen polypeptide, wherein said vaccine prevents reactivation of tuberculosis in latently infected individuals, wherein the vaccine further comprises an adjuvant comprising IC31 or DDA/TDB, with or without poly I:C, and wherein the M. tuberculosis antigen polypeptide, which is constitutively expressed, belongs to the ESX-1 secretion system and comprises: i) a first polypeptide sequence set forth in any one of SEQ ID NO. 3, 4, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 32, 33, or 34; or ii) a second polypeptide sequence that comprises at least 80% sequence identity to any one of the sequences in (i), wherein said second polypeptide sequence is immunogenic.